



INFO DAY HORIZON 2025



TargTex: The EIC Accelerator impact in Drug Development projects

TARGTEX
SME

João Seixas
Co-founder and CEO


HORIZON EUROPE



INFO DAY HORIZON 2025



TargTex: Drug development biotech company



Oncology

- CNS cancers
- Solid cancers




Cardiovascular

- Hypertrophic Cardiomyopathy

INFO DAY HORIZON 2025



TargTex: Drug development biotech company



Oncology

- CNS cancer
- Solid cancers



Cardiovascular

- Hypertrophic Cardiomyopathy

nPL4GBM – nanoPiperlongumine for Glioblastoma



1. Diagnosis



2. Surgery

3-6 weeks
recovery for
wound healing

CHEMOTHERAPY
TOXIC DRUG



RADIOTHERAPY



3. Therapy


Recurrence
After \pm 9m



INFO DAY HORIZON 2025



TargTex: Drug development biotech company



Oncology

- CNS cancer
- Solid cancers



Cardiovascular

- Hypertrophic Cardiomyopathy

nPL4GBM– nanoPiperlongumine for Glioblastoma




1. Diagnosis



2. Surgery



3-6 weeks
recovery for
wound healing



- Hydrogel **single administration** during the **surgical procedure**
- **Controlled drug release** over weeks
- Nanosized particles for **maximized diffusion**

INFO DAY HORIZON 2025



Challenges & Opportunities:

- Differentiation
- Feasibility
- Profitability



- Risk mitigation
- Asset maturity
- Pipeline Development

INFO DAY HORIZON 2025



Challenges & Opportunities:

- Differentiation
- Feasibility
- Profitability



- Risk mitigation
- Asset maturity
- Pipeline Development

The impact

- Prestige and recognition
- Financial leverage